Pregnancy in women with multiple sclerosis treated with Natalizumab

BestPractice | Sept 2019 | ECTRIMS 2019 |

In a previous study on pregnancy in multiple sclerosis (MS) women treated with natalizumab, the combination of avoiding natalizumab wash-out and the early resumption of treatment after delivery represented the best option in the perspective of maternal risk. This study is a re-appraisal of maternal outcomes in the same cohort of women after a six-year follow-up. Click and hear the result from Emilio Portaccio.